Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I/II Study of the MEK Inhibitor Selumetinib Plus DS-8201a (Trastuzumab Deruxtecan) in KRAS-Mutant, HER2-Expressing Pancreatic Ductal Adenocarcinoma

NCT07619521 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT07619521
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07619521 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I/II Study of the MEK Inhibitor Selumetinib Plus DS-8201a (Trastuzumab Deruxtecan) in KRAS-Mutant, HER2-Expressing Pancreatic Ductal Adenocarcinoma
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 1/2
Overall status
Recruiting
Start date
June 1, 2027
Completion date
September 8, 2028
Enrollment
31 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

advanced pancreatic ductal adenocarcinoma, metastatic pancreatic ductal adenocarcinoma, stage iii pancreatic cancer ajcc v8, stage iv pancreatic cancer ajcc v8, unresectable pancreatic ductal adenocarcinoma